PRMT5 and cancer: In this study, the inhibition of PRMT5/MEP50 arginine methyltransferase activity with specific short hairpin RNA (shRNA)-induced knockdown or treatment with the SAM-competitive PRMT5-specific inhibitors CMP5 and HLCL61 significantly suppressed cell proliferation via the degradation of client proteins AKT and NEMO in NDRG2low ATL and many other cancer cells.